Guide
Tirzepatide Supply in 2026: What Happens If Your Compounder Stops
The FDA proposed excluding tirzepatide from the 503B bulks list on 30 April 2026. That proposal is not final and does not touch 503A patient-specific compounding, but it
The FDA proposed excluding tirzepatide from the 503B bulks list on 30 April 2026. That proposal is not final and does not touch 503A patient-specific compounding, but it is the largest open risk to compounded supply — and almost no provider tells you what happens to a prepaid balance if it lands.
What is actually at risk?
| Pathway | Exposure to the April 2026 proposal | What that means for you |
|---|---|---|
| 503A patient-specific | Not addressed | Supply route not affected by this proposal |
| 503B outsourcing | Directly subject to it | Batch supply could be interrupted if finalised |
| Brand Zepbound | None — manufacturer supplied | Unaffected by the proposal |
“If supply is interrupted, what happens to my prepaid balance?”
A twelve-month plan takes $2,232 up front. If the pharmacy filling it cannot supply in month five, the refund position is a contract question you agreed to at checkout — and on our commitment terms field page, most providers do not publish an answer.
Ask before you prepay, not after. Get it in writing.
What are the fallbacks if it happens?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
The realistic fallback is the brand at $299 to $449, or the approved oral alternatives at $149. Both are manufacturer-supplied and carry no compounding exposure. That is a real cost increase, which is exactly why the refund question matters before you commit a year.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What should I do now?
- Ask which pathway fills your prescription, 503A or 503B. Thirty seconds.
- Ask the refund question and keep the answer.
- Weigh the term against the risk. A three-month plan saves less and strands less.
- Do not stockpile. Beyond-use dates on compounded preparations are short, and stockpiling is how people end up injecting an out-of-date preparation.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Will compounded tirzepatide stop being available?
The FDA proposed excluding it from the 503B bulks list on 30 April 2026. That is not final and does not address 503A patient-specific compounding, which is a separate pathway.
What happens to my prepaid balance if supply stops?
That is a contract question you agreed to at checkout, and most providers do not publish an answer. Ask before prepaying and get it in writing.
What are the fallbacks?
Brand Zepbound at $299 to $449 through LillyDirect, or an approved oral GLP-1 at $149. Both are manufacturer-supplied.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
- 503A Compounding Pharmacy DirectoryPharmacies
- Why Compounded GLP-1 Access Differs by StateJournal
- What PCAB Accreditation MeansPharmacies
- USP 797 Sterile Compounding, ExplainedPharmacies
- How to Verify a Compounding Pharmacy Before You EnrollJournal
Related coverage
- Compare Tirzepatide Providers Side by Side
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Tirzepatide and Hair Loss: Cause, Timing and What It Is Not
- Tirzepatide and Cardiovascular Risk: What Is Proven and What Is Pending
- Tirzepatide Injection: Sites, Rotation and What Labelling Specifies
- Tirzepatide Prior Authorisation: What Gets Approved and What Does Not
- Tirzepatide Membership Fees: When the Advertised Price Is Not the Price
- Microdose vs Standard Tirzepatide: The Price Gap and the Evidence Gap
GLP-1 Tirzepatide Rank. “Tirzepatide Supply in 2026: What Happens If Your Compounder Stops.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-shortage-supply-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.